Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%
Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.
How this was made
The 30-second read
Why it matters
Collective positive results suggest a short‑term sector rally, but individual company risks remain.
Market read
Each company’s fresh data drove a >25% price surge, offering immediate trading opportunities.
What to watch
Potential dilution from upcoming financing rounds or acquisition costs could temper upside.
Background
A roundup of recent biotech earnings and trial updates, each triggering sizable intraday moves.
Ticker impact
Genmab posted positive Phase 3 data for petosemtamab+Keytruda, driving a 33% share jump.
upward pressure as investors price in potential approval and market expansion
Phase 3 results showing 50% mortality reduction are material and new, prompting a strong price move.
Pulmonx reported Q3 revenue growth and narrowed loss, raising its 2026 outlook, sending the stock up 33%.
upward as the market rewards higher revenue guidance and margin outlook
Quarterly results and guidance lift investor confidence, a fresh catalyst.
Axogen posted strong Q3 revenue, profit and raised 2026 guidance, pushing the stock up 32%.
upward pressure from higher earnings and acquisition‑related growth expectations
First‑report earnings with guidance raise are material for a small‑cap biotech.
OrthoPediatrics delivered record Q3 revenue and narrowed loss, raising its 2026 outlook, lifting the stock 29%.
upward as investors value improved profitability and higher guidance
Fresh earnings and guidance are new, material information.
Replimune narrowed its Q2 loss and reported cash runway, sending the stock up 25%.
upward as the market rewards lower loss and sufficient liquidity
First‑report loss improvement and cash update are material for the stock.
Market effects
Biotech sector gains momentum as multiple companies report strong trial data and earnings, potentially lifting peers.
U.S. biotech indices likely see short‑term upside.
Limited to biotech investors; no broad macro impact.
Counterpoint
Some investors may wait for regulatory approval risk before adding positions.
Key entities
- companyGenmab A/S
Danish biotech developing antibody therapies.
- companyPulmonx Corporation
Medical device maker focused on lung treatments.
- companyAxogen, Inc.
Developer of regenerative medicine products.
- companyOrthoPediatrics Corp.
Pediatric orthopedic device manufacturer.
- companyReplimune Group, Inc.
Immuno‑oncology biotech.
